Bard PowerPort Catheter

● CAMPAIGN OPEN DISCOVERY / BELLWETHER SELECTION 2 signals
Fracture, Migration, Thrombosis, Infection  ·  Bard PowerPort Implantable Port Catheter
DEFENDANT
C.R. Bard / Becton Dickinson (BD)
MDL / DOCKET
MDL 3081
D. Arizona
JUDGE
Hon. David Campbell
PLAINTIFFS
8,000+
BELLWETHER / TRIAL
Est. 2025–2026
SETTLEMENT STATUS
None — active discovery
📋 Case Overview

The Bard PowerPort is an implantable venous access device used primarily for chemotherapy patients. Plaintiffs allege the device is defectively designed using Chronoflex polyurethane that degrades and fractures inside the body, causing catheter fragments to migrate to the heart, lungs, or bloodstream. MDL 3081 was formed in Arizona in 2023 and is in active discovery with thousands of plaintiffs.

⚗ CAUSATION SUMMARY

Chronoflex AL polyurethane used in the catheter is alleged to degrade over time, becoming brittle and fracturing. Fragments can migrate to the heart or pulmonary arteries, causing life-threatening complications. Design defect and failure-to-warn are the primary theories. Internal Bard documents showing knowledge of the degradation issue are key causation evidence.

⚖️ Litigation Status ACTIVE
MDL / Court
MDL 2641 — D. Arizona (Judge David Campbell)
Active Plaintiffs
4,000+

MDL 2641 involves Bard PowerPort implantable port catheters alleged to fracture and migrate, causing serious injury. Active discovery. Bellwether selection underway. BD (Becton Dickinson) is the defendant following acquisition of Bard.

Key Verdicts & Settlements
⚖️
Bellwether trials projected 2025
First trials will establish liability framework and per-case values.
🔬
Polyurethane fracture defect established
Internal Bard documents show awareness of fracture risk. Strong design defect theory.
⏸️
Filing trend: Active. Campaign open. Bellwether outcomes in 2025 will be critical. Strong internal document record supports liability theory.
📍 Geographic Exposure
Nationwide — used in cancer treatment centers across all states
No geographic restriction; device implanted in oncology patients nationwide
🏢 Key Defendants
DEFENDANT
ROLE
INTEL NOTE
C.R. Bard Inc.
Manufacturer and designer
Primary defendant; knew of Chronoflex degradation issues
Becton Dickinson (BD)
Parent company (acquired Bard 2017)
Co-defendant; significant financial exposure
✅ Campaign Eligibility Criteria
Had Bard PowerPort device implanted (any model)
Experienced catheter fracture, migration, embolism, thrombosis, or infection
Device-related injury required intervention, surgery, or hospitalization
Within 2 years of injury discovery or device removal
These criteria reflect general case strength indicators and are not legal advice. Contact CloudIntake to screen individual claimants.
📅 Litigation Timeline
1999
Bard PowerPort introduced; Chronoflex polyurethane used in construction
2012
FDA receives increasing adverse event reports of port fractures and migrations
2020–2022
First mass tort lawsuits filed; plaintiff law firms begin national campaigns
2023
MDL 3081 formed in D. Arizona before Judge Campbell
2024
Discovery underway; 8,000+ cases filed; bellwether selection in progress
Bard PowerPort Catheter — Intelligence Feed LIVE
📰 NEWS
Bard PowerPort Lawsuit
Mar 13, 2026 Lawsuit Information Center Read Source →
📰 NEWS
Bard PowerPort under fire for dangerous defects
Mar 13, 2026 Class Action Lawsuits Read Source →
Feed All Torts
MASS TORT AD AGENCY
Targeted. Compliant. Mass tort-specific.
Generic PI ads don't work for mass torts. MTAA builds campaigns engineered for Bard PowerPort Catheter plaintiff screening.
Get a Free Consult →
Plaintiff attorneys only · mtaa.ai
JACOB SCORE™
Bard PowerPort Catheter
55 / 100
ScienceModerate
MomentumModerate
CampaignModerate
TimelineDeveloping
VerdictsDeveloping
DEVICE MDL · BELLWETHER PENDING
Jacob Score™ — Methodology & Legal Disclaimers
The Jacob Score is a composite 1–100 litigation opportunity index for mass torts, produced by the TortIntel editorial team at Mass Tort Ad Agency. It is updated periodically as litigation conditions change.

Score Dimensions (each rated 1–5)

Science — Peer-reviewed study quality and quantity, relative risk magnitude, replication across independent research groups, FDA or regulatory action taken, and estimated Daubert survivability based on published expert testimony and prior rulings.

Momentum — MDL formation and phase, plaintiff count trajectory, case consolidation activity, and overall litigation velocity.

Campaign — Current filing window status, case saturation, defendant solvency, estimated qualifying population size, and co-defendant dynamics.

Timeline — Proximity to first expected resolution or bellwether trial, current discovery or Daubert phase, and estimated time-to-value for a signed plaintiff.

Verdicts — Confirmed plaintiff jury verdicts, bellwether trial win/loss record, and size or certainty of any established settlement fund. 1 = pre-trial · 2 = mixed early results · 3 = partial settlements or initial wins · 4 = confirmed large verdicts or funded settlement · 5 = landmark verdicts with formal settlement program.

LEGAL DISCLAIMERS

The Jacob Score and all associated content on TortIntel.ai is provided solely for mass tort business intelligence and law firm marketing decision-making purposes. It does not constitute legal advice, litigation strategy advice, or a recommendation to file or refrain from filing any lawsuit.

The Jacob Score is an editorial opinion based on publicly available data including court filings, published scientific literature, regulatory actions, and reported settlement information. It is not a guarantee of future litigation outcomes. Past verdicts and settlements are not predictive of future results in any specific case.

TortIntel.ai and Mass Tort Ad Agency make no representation that any score is complete, accurate, or current. Litigation conditions change rapidly. Attorneys must conduct independent due diligence and consult qualified co-counsel before making any case acquisition or litigation funding decisions based on this or any other intelligence tool.

This score must not be used to evaluate, accept, or reject any individual plaintiff’s case. Case-specific merit depends on individual facts, applicable state law, expert medical and scientific analysis, and jurisdiction-specific statutes of limitations — all of which are beyond the scope of this tool.

No attorney-client relationship is created by use of this platform. TortIntel.ai is not a law firm and does not provide legal services. © 2026 Mass Tort Ad Agency / TortIntel.ai. All rights reserved.
DATA ACCURACY
See something incorrect? Reach out and we'll fix it.
🔔 Alert Me
Get notified when Bard PowerPort Catheter updates.
✓ You're subscribed. We'll notify you of key developments.
TORTINTEL PRO
Abuse Discovery Tracker
Emerging institutional abuse cases — church, scouting, youth programs. Real-time defendant monitoring, filing window alerts, and filing cluster detection.
View Pro Features →